Obesity and Chronic Kidney Disease (original) (raw)

Abstract

This article summarizes the current hypotheses that link visceral obesity and kidney malfunction and provides information on the epidemiology and renal pathology resulting from visceral obesity.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (71)

  1. Haslam DW, James WP. Obesity. Lancet. 2005;366: 1197-209.
  2. Pereira MA, Kartashov AI, Ebbeling CB, Van Horn L, Slattery ML, Jacobs DR Jr, et al. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet. 2005;365:36-42.
  3. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368:1681-8.
  4. Zimmet P, Alberti G, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents. Lancet. 2007;369:2059-61.
  5. Kipping RR, Jago R, Lawlor DA. Obesity in children. Part 1: epidemiology, measurement, risk factors, and screening. BMJ. 2008;337:a1824.
  6. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352:1138-45.
  7. Mann CC. Public health. Provocative study says obe- sity may reduce U.S. life expectancy. Science. 2005; 307:1716-7.
  8. Hall JE, Kuo JJ, da Silva AA, de Paula RB, Liu J, Tallam L. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens. 2003;12:195-200.
  9. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12:1211-7.
  10. Griffin KA, Kramer H, Bidani AK. Adverse renal con- sequences of obesity. Am J Physiol Renal Physiol. 2008;294:F685-96.
  11. Tomaszewski M, Charchar FJ, Maric C, McClure J, Crawford L, Grzeszczak W, et al. Glomerular hyper- filtration: a new marker of metabolic risk. Kidney Int. 2007;71:816-21.
  12. Krikken JA, Lely AT, Bakker SJ, Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int. 2007;71:260-5.
  13. Rook M, Bosma RJ, van Son WJ, Hofker HS, van der Heide JJ, ter Wee PM, et al. Nephrectomy elicits impact of age and BMI on renal hemodynamics: lower postdonation reserve capacity in older or overweight kidney donors. Am J Transplant. 2008;8:2077-85.
  14. Bosma RJ, Kwakernaak AJ, van der Heide JJ, de Jong PE, Navis GJ. Body mass index and glomerular hyperfiltration in renal transplant recipients: cross-sectional analysis and long-term impact. Am J Transplant. 2007;7:645-52.
  15. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol. 2003;14:1480-6.
  16. Perrini S, Leonardini A, Laviola L, Giorgino F. Biological specificity of visceral adipose tissue and therapeutic intervention. Arch Physiol Biochem. 2008;114:277-86.
  17. Phillips LK, Prins JB. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep. 2008;10:156-64.
  18. Bays HE, Gonzalez-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipo- cyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008;6:343-68.
  19. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, et al. Obesity-associated improve- ments in metabolic profile through expansion of ad- ipose tissue. J Clin Invest. 2007;117:2621-37.
  20. Petersen KF, Shulman GI. Etiology of insulin resis- tance. Am J Med. 2006;119 Suppl 1:S10-6.
  21. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of an effect of liposuc- tion on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350:2549-57.
  22. Pinto-Sietsma SJ, Navis G, Janssen WM, de Zeeuw D, Gans RO, de Jong PE. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis. 2003;41:733-41.
  23. Bonnet F, Marre M, Halimi JM, Stengel B, Lange C, Laville M, et al. Waist circumference and the meta- bolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR study. J Hypertens. 2006;24:1157-63.
  24. Arner P. Introduction: the inflammation orchestra in adipose tissue. J Intern Med. 2007;262:404-7.
  25. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005;16:1091-8.
  26. Lastra G, Manrique C, Sowers JR. Obesity, cardiom- etabolic syndrome, and chronic kidney disease: the weight of the evidence. Adv Chronic Kidney Dis. 2006;13:365-73.
  27. Rocchini AP, Katch V, Kveselis D, Moorehead C, Martin M, Lampman R, Gregory M. Insulin and renal sodium retention in obese adolescents. Hypertension. 1989;14:367-74.
  28. Landsberg L. Insulin-mediated sympathetic stimula- tion: role in the pathogenesis of obesity-related hy- pertension (or, how insulin affects blood pressure, and why). J Hypertens. 2001;19:523-8.
  29. Sarafidis PA, Whaley-Connell A, Sowers JR, Bakris GL. Car- diometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr. 2006;1:58-65.
  30. Cassis LA, Police SB, Yiannikouris F, Thatcher SE. Local adipose tissue renin-angiotensin system. Curr Hypertens Rep. 2008;10:93-8.
  31. Vogt B, Bochud M, Burnier M. The association of aldo- sterone with obesity-related hypertension and the met- abolic syndrome. Semin Nephrol. 2007;27:529-37.
  32. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007;49:355-64.
  33. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211-6.
  34. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipa- tikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43:358-63.
  35. Verhave JC, Hillege HL, Burgerhof JG, Janssen WM, Gansevoort RT, Navis GJ, et al. Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med. 2004;256:324-30.
  36. Bello AK, de Zeeuw D, El Nahas M, Brantsma AH, Bakker SJ, de Jong PE, et al. Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant. 2007;22:1619-27.
  37. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis. 2002;39:1-11.
  38. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008; 118:1645-56.
  39. Sanchez-Lozada LG, Tapia E, Jimenez A, Bautista P, Cristobal M, Nepomuceno T, et al. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol. 2007;292:F423-9.
  40. Elsayed EF, Tighiouart H, Weiner DE, Griffith J, Salem D, Levey AS, et al. Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J Kidney Dis. 2008;52:49-57.
  41. Sanches FM, Avesani CM, Kamimura MA, Lemos MM, Axelsson J, Vasselai P, et al. Waist circumference and visceral fat in CKD: a cross-sectional study. Am J Kidney Dis. 2008;52:66-73.
  42. Praga M, Hernandez E, Andres A, Leon M, Ruilope LM, Rodicio JL. Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron. 1995;70:35-41.
  43. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21-8.
  44. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Associ- ation between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73:19-33.
  45. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870-6.
  46. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among non- diabetic adults. J Am Soc Nephrol. 2005;16:2134-40.
  47. Foster MC, Hwang SJ, Larson MG, Lichtman JH, Parikh NI, Vasan RS, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis. 2008;52:39-48.
  48. Ryu S, Chang Y, Woo HY, Kim SG, Kim DI, Kim WS, et al. Changes in body weight predict CKD in healthy men. J Am Soc Nephrol. 2008;19:1798-805.
  49. Young JA, Hwang SJ, Sarnak MJ, Hoffmann U, Massaro JM, Levy D, et al. Association of visceral and subcu- taneous adiposity with kidney function. Clin J Am Soc Nephrol. 2008;3:1786-91.
  50. Iseki K, Tohyama K, Matsumoto T, Nakamura H. High prevalence of chronic kidney disease among patients with sleep related breathing disorder (SRBD). Hyper- tens Res. 2008;31:249-55.
  51. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335:1134.
  52. Adams KF, Leitzmann MF, Albanes D, Kipnis V, Moore SC, Schatzkin A, et al. Body size and renal cell cancer incidence in a large US cohort study. Am J Epidemiol. 2008;168:268-77.
  53. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-78.
  54. Obligado SH, Goldfarb DS. The association of neph- rolithiasis with hypertension and obesity: a review. Am J Hypertens. 2008;21:257-64.
  55. Nasr SH, D'Agati VD, Said SM, Stokes MB, Largoza MV, Radhakrishnan J, et al. Oxalate nephropathy compli- cating Roux-en-Y gastric bypass: an underrecognized cause of irreversible renal failure. Clin J Am Soc Neph- rol. 2008;3:1676-83.
  56. Weisinger JR, Kempson RL, Eldridge FL, Swenson RS. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med. 1974;81:440-7.
  57. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging ep- idemic. Kidney Int. 2001;59:1498-509.
  58. Chen HM, Liu ZH, Zeng CH, Li SJ, Wang QW, Li LS. Podocyte lesions in patients with obesity-related glo- merulopathy. Am J Kidney Dis. 2006;48:772-9.
  59. Serra A, Romero R, Lopez D, Navarro M, Esteve A, Perez N, et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 2008;73:947-55.
  60. Rea DJ, Heimbach JK, Grande JP, Textor SC, Taler SJ, Prieto M, et al. Glomerular volume and renal histol- ogy in obese and non-obese living kidney donors. Kidney Int. 2006;70:1636-41.
  61. Altiparmak MR, Pamuk ON, Pamuk GE, Apaydin S, Ozbay G. Diffuse diabetic glomerulosclerosis in a pa- tient with impaired glucose tolerance: report on a patient who later develops diabetes mellitus. Neth J Med. 2002;60:260-2.
  62. Souraty P, Nast CC, Mehrotra R, Barba L, Martina J, Adler SG. Nodular glomerulosclerosis in a patient with metabolic syndrome without diabetes. Nat Clin Pract Nephrol. 2008;4:639-42.
  63. Praga M, Morales E. Obesity, proteinuria and progres- sion of renal failure. Curr Opin Nephrol Hypertens. 2006;15:481-6.
  64. Praga M, Hernandez E, Herrero JC, Morales E, Revilla Y, Diaz-Gonzalez R, et al. Influence of obesity on the ap- pearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int. 2000;58:2111-8.
  65. Gonzalez E, Gutierrez E, Morales E, Hernandez E, Andres A, Bello I, et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and rem- nant kidney. Kidney Int. 2005;68:263-70.
  66. Praga M. Synergy of low nephron number and obe- sity: a new focus on hyperfiltration nephropathy. Nephrol Dial Transplant. 2005;20:2594-7.
  67. Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight pa- tients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41:319-27.
  68. Alexander MP, Patel TV, Farag YM, Florez A, Rennke HG, Singh AK. Am J Kidney Dis. 2009;53:751-9.
  69. Bonnet F, Deprele C, Sassolas A, Moulin P, Alamartine E, Berthezene F, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis. 2001;37:720-7.
  70. Kaartinen K, Syrjanen J, Porsti I, Harmoinen A, Pas- ternack A, Huhtala H, et al. Insulin resistance and the progression of IgA glomerulonephritis. Nephrol Dial Transplant. 2007;22:778-83.
  71. Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70-4.